These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15950315)

  • 21. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
    Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs.
    Gradowski JF; Mantha GS; Hunt JL; Dacic S
    Diagn Mol Pathol; 2007 Jun; 16(2):87-90. PubMed ID: 17525677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
    J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
    Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO
    Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.
    Fong Y; Lin YS; Liou CP; Li CF; Tzeng CC
    Respirology; 2010 May; 15(4):700-5. PubMed ID: 20409020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
    Westra WH; Baas IO; Hruban RH; Askin FB; Wilson K; Offerhaus GJ; Slebos RJ
    Cancer Res; 1996 May; 56(9):2224-8. PubMed ID: 8616876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.
    Mammano E; Belluco C; Sciro M; Mencarelli R; Agostini M; Michelotto M; Marchet A; Nitti D
    Anticancer Res; 2006; 26(5A):3547-50. PubMed ID: 17094480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor gene mutations in early pulmonary adenocarcinomas.
    Nakamura H; Kawasaki N; Taguchi M; Kato H
    Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):87-92. PubMed ID: 17505415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
    Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
    J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.
    Marchetti A; Pellegrini S; Bertacca G; Buttitta F; Gaeta P; Carnicelli V; Nardini V; Griseri P; Chella A; Angeletti CA; Bevilacqua G
    J Pathol; 1998 Mar; 184(3):240-6. PubMed ID: 9614374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
    Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
    Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.
    Franco-Hernandez C; Martinez-Glez V; Arjona D; de Campos JM; Isla A; Gutierrez M; Vaquero J; Rey JA
    Cancer Genet Cytogenet; 2007 Feb; 173(1):63-7. PubMed ID: 17284372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
    Kohno T; Kakinuma R; Iwasaki M; Yamaji T; Kunitoh H; Suzuki K; Shimada Y; Shiraishi K; Kasuga Y; Hamada GS; Furuta K; Tsuta K; Sakamoto H; Kuchiba A; Yamamoto S; Kanai Y; Tsugane S; Yokota J
    Carcinogenesis; 2010 Oct; 31(10):1794-9. PubMed ID: 20688833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.
    Tomonaga N; Nakamura Y; Yamaguchi H; Ikeda T; Mizoguchi K; Motoshima K; Doi S; Nakatomi K; Iida T; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2013 Sep; 14(5):521-6. PubMed ID: 23786997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.